2,2,4,4-tetramethyl-pentan-3-one O-tert-butyl-oxime | 73996-70-0

• 分子结构分类: 有机化合物 - 有机氮化合物
• 英文名称: 2,2,4,4-tetramethyl-pentan-3-one O-tert-butyl-oxime
• 英文别名: 2,2,4,4-tetramethyl-N-[(2-methylpropan-2-yl)oxy]pentan-3-imine
• CAS: 73996-70-0
• 化学式: C₁₃H₂₇NO
• 分子量: 213.363
• InChiKey: VDKMFAIZIZLNLH-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.3
• 重原子数：
  15
• 可旋转键数：
  4
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.92
• 拓扑面积：
  21.6
• 氢给体数：
  0
• 氢受体数：
  2

反应信息

• 作为产物：
  描述：

  di-tert-butyliminoxyl 、 叔丁基锂 生成 2,2,4,4-tetramethyl-pentan-3-one O-tert-butyl-oxime
  参考文献：
  名称：

  二叔丁基亚氨基氧基与有机金属化合物的反应

  摘要：

  标题亚氨基氧基基团1与格氏试剂和有机锂试剂RM的反应最初与基团R-一起产生二叔丁基酮肟2（盐形式）。该自由基R-可以与氧上的未反应的亚氨基氧基结合而得到肟醚3。由于空间原因，很难对氮进行攻击，因此硝酮6未形成或仅以痕量存在。从未观察到对碳的甚至更受阻碍的侵蚀，即没有形成（中间体）亚硝基化合物。相对反应性的甲基和苯基基团可以从溶剂（二乙醚）中提取氢。以这种方式形成α-乙氧基乙基，其可以与氧上的亚氨基氧基结合，产生乙缩醛状肟醚7。

  DOI：

  10.1016/0040-4020(79)87027-1

文献信息

• Compositions and methods for the depletion of CD137+ cells
  申请人：Magenta Therapeutics, Inc.

  公开号：US10434185B2

  公开（公告）日：2019-10-08

  The invention provides methods of preventing and treating graft-versus-host-disease and autoimmune diseases, such as those arising from transplant therapy, by selective depletion of hematopoietic cells through the use of antibody-drug conjugates and ligand-drug conjugates that specifically bind CD137. The compositions and methods described herein can be used to treat a variety of pathologies, including stem cell disorders and other blood conditions.

  本发明提供了预防和治疗移植物抗宿主疾病和自身免疫性疾病的方法，例如通过使用特异性结合CD137的抗体-药物共轭物和配体-药物共轭物，选择性地消耗造血细胞。本文所述的组合物和方法可用于治疗各种病症，包括干细胞疾病和其他血液疾病。
• US20140274958A1
  申请人：——

  公开号：US20140274958A1

  公开（公告）日：2014-09-18
• AMATOXIN DERIVATIVES AND CELL-PERMEABLE CONJUGATES THEREOF AS INHIBITORS OF RNA POLYMERASE
  申请人：MENDELSOHN Brian Alan

  公开号：US20150218220A1

  公开（公告）日：2015-08-06

  The present invention relates to analogs of alpha-amanitin, methods of inhibiting RNA polymerase with such compounds, conjugates comprising such compounds, compositions comprising such compounds and conjugates, and methods of treatment using such conjugates.
• GLYCOENGINEERED ANTIBODY DRUG CONJUGATES
  申请人：Genzyme Corporation

  公开号：US20160136299A1

  公开（公告）日：2016-05-19

  The current disclosure provides binding polypeptides (e.g., antibodies), and targeting moiety conjugates thereof, comprising a site-specifically engineered glycan linkage within native or engineered glycans of the binding polypeptide. The current disclosure also provides nucleic acids encoding the antigen-binding polypeptides, recombinant expression vectors and host cells for making such antigen-binding polypeptides. Methods of using the antigen-binding polypeptides disclosed herein to treat disease are also provided.
• COMPOSITIONS AND METHODS FOR THE DEPLETION OF CD117+ CELLS
  申请人：Magenta Therapeutics, Inc.

  公开号：US20170360954A1

  公开（公告）日：2017-12-21

  The invention provides compositions and methods useful for the depletion of CD117+ cells and for the treatment of various hematopoietic diseases, metabolic disorders, cancers, and autoimmune diseases, among others. Described herein are antibodies, antigen-binding fragments, ligands, and conjugates thereof that can be applied to effect the treatment of these conditions, for instance, by depleting a population of CD117+ cells in a patient, such as a human. The compositions and methods described herein can be used to treat a disorder directly, for instance, by depleting a population of CD117+ cancer cells or autoimmune cells. The compositions and methods described herein can also be used to prepare a patient for hematopoietic stem cell transplant therapy and to improve the engraftment of hematopoietic stem cell transplants by selectively depleting endogenous hematopoietic stem cells prior to the transplant procedure.